Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;34(11):3047-3049.
doi: 10.1038/s41375-020-01030-2. Epub 2020 Aug 27.

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Lindsey E Roeker  1 , David A Knorr  2 , Melissa S Pessin  3 , Lakshmi V Ramanathan  3 , Meghan C Thompson  2 , Lori A Leslie  4 , Andrew D Zelenetz  5 , Anthony R Mato  2
Affiliations

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Lindsey E Roeker et al. Leukemia. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

ER has received grant funding from American Society of Hematology outside of the submitted work and has minority ownership interest in AbbVie and Abbott Laboratories; LVR has received institutional research funding outside of submitted work from Abbott, IBM, and BioPortal; LAL is a member of speaker’s bureau for Seattle Genetics, Celgene/BMS, KitePharma, BeiGene, Pharmacyclics/Janssen, AstraZeneca, Epizyme, Karyopharm, advisory board participant for Bayer, Seattle genetics, ADC therapeutics, Abbvie, Janssen, Pharmacyclics, Kite, AstraZeneca, TG Therapeutics; ADZ has received research grants from Abbvie, Adaptive Biotechnologies, BMS, BeiGene, Genentech/Roche, MEI Pharma, consulting fees from Amgen, AstraZeneca, BeiGene, Genentech/Roche, Janssen, JUNO/Celgene/BMS, Kite/Gilead, MEI Pharma, Pfizer, Pharmacyclics, Sandoz/Novartis, and serves on the scientific advisory board of Adaptive Biotechnologies, Lymphoma Research Foundation; ARM has received grants, personal fees and other from TG Therapeutics, grants and personal fees from Pharmacyclics, grants and personal fees from Janssen, grants and other from Celgene, grants and personal fees from Genentch, grants and personal fees from Abbvie, grants and personal fees from Adaptive, grants from Loxo, grants from Sunesis, grants from Regeneron, grants from DTRM, personal fees from Beigene, grants and personal fees from AstraZenica.

Comment in

References

    1. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: the first report. J Infect. 2020;81:147–78. doi: 10.1016/j.jinf.2020.03.012. - DOI - PMC - PubMed
    1. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–8. doi: 10.1038/s41591-020-0897-1. - DOI - PubMed
    1. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa344. - DOI - PMC - PubMed
    1. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) Clin Infect Dis. 2020;71:778–85. doi: 10.1093/cid/ciaa310. - DOI - PMC - PubMed
    1. Du Z, Zhu F, Guo F, Yang B, Wang T. Detection of antibodies against SARS-CoV-2 in patients with COVID-19. J Med Virol. 2020 doi: 10.1002/jmv.25820. - DOI - PMC - PubMed

Publication types

MeSH terms